Cordlife Group Limited (P8A.SI)
- Previous Close
0.1580 - Open
0.1550 - Bid 0.1500 x --
- Ask 0.1550 x --
- Day's Range
0.1550 - 0.1550 - 52 Week Range
0.1190 - 0.1850 - Volume
8,500 - Avg. Volume
77,828 - Market Cap (intraday)
39.728M - Beta (5Y Monthly) 0.52
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0700 - Earnings Date Mar 1, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date May 6, 2022
- 1y Target Est
--
Cordlife Group Limited, an investment holding company, provides cord blood banking services in Singapore, Hong Kong, India, Malaysia, the Philippines, and internationally. It operates in two segments, Banking and Diagnostics. The Banking segment collects, processes, banks, and tests biological materials, such as cord blood, lining, and tissue samples. The Diagnostics segment offers diagnostic testing services, such as newborn genetic and metabolic screenings; pediatric vision and ear screenings; pediatric allergen test; and genetic talent test services. The company also provides corneal lenticule banking, gut microbiome banking, and lifestyle genetic screening services for adults. In addition, it offers Moms Up, a mobile application that offers parenting resources, as well as sprouts for health, wellness, and lifestyle needs. Further, the company provides medical laboratory, marketing, and property investment services, as well as medical and pharmaceutical research and development and consulting services. Cordlife Group Limited was incorporated in 2001 and is based in Singapore.
www.cordlife.com--
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: P8A.SI
View MorePerformance Overview: P8A.SI
Trailing total returns as of 5/9/2025, which may include dividends or other distributions. Benchmark is STI Index (^STI) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: P8A.SI
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: P8A.SI
View MoreValuation Measures
Market Cap
39.73M
Enterprise Value
-18.43M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.43
Price/Book (mrq)
0.34
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-67.11%
Return on Assets (ttm)
-6.68%
Return on Equity (ttm)
-14.69%
Revenue (ttm)
27.84M
Net Income Avi to Common (ttm)
-18.69M
Diluted EPS (ttm)
-0.0700
Balance Sheet and Cash Flow
Total Cash (mrq)
60.58M
Total Debt/Equity (mrq)
2.04%
Levered Free Cash Flow (ttm)
-7.73M